Sentinel Oncology Limited p70S6 kinase inhibitor licensing opportunity
Sentinel Oncology, the Cambridge based cancer company focused on the discovery of novel treatments for cancer patients is pleased to announce that its p70S6 kinase programme is available for partnering.
The novel small molecule leads have been shown to inhibit p70S6 kinase at therapeutically relevant concentrations and as such represent a significant opportunity for companies wishing to begin or expand or consolidate their activities in this exciting research area.
For more information about the Sentinel Oncology p70S6 kinase programme, visit our website at http://www.sentineloncology.com/solutions/rnd/p70s6k/ or contact us to hold a collaborative discussion.
February 05, 2009
Events
Sentinel Oncology will be participating in the following events
15th April 2010
Anglo Nordic Biotech conference
London, UK
3rd-6th May 2010
BIO International Convention
Chicago, IL, USA
4th-8th June 2010
ASCO
Chicago, IL, USA
10th-12th October 2010
BPE
London, UK
9th December 2010
Genesis conference
London, UK